Krebs Biochemicals & Industries Limited reported earnings results for the fourth quarter and full year ended March 31, 2024. For the fourth quarter, the company reported sales was INR 119.73 million compared to INR 114.61 million a year ago. Revenue was INR 121.83 million compared to INR 116.54 million a year ago. Net loss was INR 58.47 million compared to INR 69.4 million a year ago. Basic loss per share from continuing operations was INR 2.72 compared to INR 3.07 a year ago. Diluted loss per share from continuing operations was INR 2.72 compared to INR 3.07 a year ago.
For the full year, sales was INR 504.22 million compared to INR 521.34 million a year ago. Revenue was INR 508.73 million compared to INR 527.55 million a year ago. Net loss was INR 197.28 million compared to INR 246.92 million a year ago. Basic loss per share from continuing operations was INR 9.16 compared to INR 11.3 a year ago. Diluted loss per share from continuing operations was INR 9.16 compared to INR 11.3 a year ago.